Jenscare Scientific Co (HKSE:09877) Other Current Payables: HK$35.4 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:09877 Jenscare Scientific Co Ltd HKSE:09877
33 GF Score
Price HK$7.28
! 4 Warning Signs
View Full Analysis

What is Jenscare Scientific Co Other Current Payables?

Jenscare Scientific Co HKSE:09877 -1.69% 33 Other Current Payables is HK$35.4 Mil as of Dec. 2025. GuruFocus rates HKSE:09877 with a GF Score™ of 33/100. The stock has 4 warning signs investors should review.

Jenscare Scientific Co's Other Current Payables for the quarter that ended in Dec. 2025 was HK$35.4 Mil.

Jenscare Scientific Co's quarterly Other Current Payables increased from Dec. 2024 (HK$22.2 Mil) to Jun. 2025 (HK$28.1 Mil) and increased from Jun. 2025 (HK$28.1 Mil) to Dec. 2025 (HK$35.4 Mil).

Jenscare Scientific Co's annual Other Current Payables declined from Dec. 2023 (HK$31.2 Mil) to Dec. 2024 (HK$22.2 Mil) but then increased from Dec. 2024 (HK$22.2 Mil) to Dec. 2025 (HK$35.4 Mil).

Jenscare Scientific Co Other Current Payables Related Terms

Jenscare Scientific Co Other Current Payables Historical Data

* Premium members only.

The historical data trend for Jenscare Scientific Co's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jenscare Scientific Co Other Current Payables Chart

Jenscare Scientific Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial 34.82 35.51 31.23 22.22 35.44

Jenscare Scientific Co Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 36.85 22.22 28.09 35.44 54.09
HKSE:09877
33GF Score
Jenscare Scientific Co Ltd HKSE:09877
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jenscare Scientific Co Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of HK$35.4 Mil mean?
Jenscare Scientific Co (HKSE:09877) has a Other Current Payables of HK$35.4 Mil as of Dec. 2025. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Jenscare Scientific Co and its competitors.
Is Jenscare Scientific Co's Other Current Payables too high?
Jenscare Scientific Co's current Other Current Payables is HK$35.4 Mil. Overall, Jenscare Scientific Co has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Jenscare Scientific Co's Other Current Payables compare to ABT and SYK?
Jenscare Scientific Co's Other Current Payables of HK$35.4 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Medical Devices & Instruments company?
A good Other Current Payables depends on the Medical Devices & Instruments industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Jenscare Scientific Co and its competitors. Jenscare Scientific Co's current Other Current Payables is HK$35.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jenscare Scientific Co stock overvalued right now?
Jenscare Scientific Co (HKSE:09877) has a current Other Current Payables of HK$35.4 Mil. The current Other Current Payables is HK$35.4 Mil. Jenscare Scientific Co's overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Jenscare Scientific Co (HKSE:09877), the current Other Current Payables is HK$35.4 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Jenscare Scientific Co Business Description

Address No. 777 Binhai 4th Road, Block 5, B Area, Hangzhou Bay New Area, Zhejiang Province, Ningbo, CHN
Jenscare Scientific Co Ltd is engaged in the manufacturing, research, and development of medical devices. The company develops interventional products for the treatment of structural heart disease. The company's core products include LuX-Valve and Ken-Valve. LuX-Valve is a transcatheter tricuspid valve replacement system designed for patients with severe tricuspid regurgitation and high surgical risk. Ken-Valve is designed for the treatment of severe aortic regurgitation or combined with aortic stenosis. The company also develops product candidates for the treatment of mitral valve diseases and medical devices for the treatment of heart failure. Geographically, the company generates the majority of its revenue from the Chinese mainland.
33GF Score

Get the complete analysis for HKSE:09877

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$7.28
Price